NASDAQ:ACOR

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$0.66
$15.60
52-Week Range
N/A
Volume
416,900 shs
Average Volume
119,299 shs
Market Capitalization
$820,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ACOR stock logo

About Acorda Therapeutics Stock (NASDAQ:ACOR)

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

ACOR Stock News Headlines

Acorda Therapeutics Announces Delisting from Nasdaq
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update
Acorda Therapeutics Inc.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Stocks to Watch: PVH, Canoo, Acorda Therapeutics
3 Biotech Stocks to Watch in March for Success
Acorda: No policy vs. TikTok use in PNP
See More Headlines
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
4/24/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACOR
CUSIP
00484M10
Employees
111
Year Founded
1995

Profitability

Net Income
$-252,850,000.00
Net Margins
-214.95%
Pretax Margin
-251.65%

Debt

Sales & Book Value

Annual Sales
$117.63 million
Cash Flow
$33.05 per share
Book Value
($127.17) per share

Miscellaneous

Free Float
1,210,000
Market Cap
$819,640.00
Optionable
No Data
Beta
1.40

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Ron Cohen M.D. (Age 68)
    Founder, CEO, President & Director
    Comp: $984.15k
  • Mr. Michael A. Gesser M.B.A. (Age 61)
    Chief Financial Officer
    Comp: $459.15k
  • Mr. Kerry M. Clem (Age 54)
    Chief Commercial Officer
    Comp: $592.23k
  • Mr. Robert Morales (Age 56)
    Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller
  • Ms. Felicia Vonella
    Vice President of Investor Relations
  • Mr. Neil S. Belloff Esq. (Age 64)
    General Counsel & Corporate Secretary
  • Ms. Tierney Saccavino
    Executive Vice President of Corporate Communications
  • Ms. Denise J. Duca
    Executive Vice President of Human Resources
  • Mr. Andrew Mayer J.D.
    Senior Vice President
  • Sofia Ali
    Senior VP of Operations & Strategic Planning

ACOR Stock Analysis - Frequently Asked Questions

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 8,100 shares, a drop of 14.7% from the March 15th total of 9,500 shares. Based on an average trading volume of 113,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.7% of the company's shares are sold short.
View Acorda Therapeutics' Short Interest
.

When is Acorda Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ACOR earnings forecast
.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) EPS for the quarter, beating the consensus estimate of ($31.20) by $2.60. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to analyst estimates of $30.57 million. Acorda Therapeutics had a negative net margin of 214.95% and a negative trailing twelve-month return on equity of 2,206.93%.

When did Acorda Therapeutics' stock split?

Acorda Therapeutics shares reverse split on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

How do I buy shares of Acorda Therapeutics?

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACOR) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners